Possible therapeutic strategies include checkpoint blockade, e.g., blockade of CTLA-4, PD1, PD-L1; targeting angiogenesis, e.g., anti-VEGF drugs; or inhibiting tumor-specific metabolic pathways, e.g., IDO1 inhibitors. This evidence concerns the gene SNCA and neoplasm.